20 May 2026
Perspectives from a neurologist and a cardiologist on LAA closure vs DOAC for stroke prevention
PCR Perspectives
Summary
In this discussion, Lorenz Räber and David Seiffge review the latest evidence on percutaneous left atrial appendage (LAA) closure for stroke prevention, focusing on the CLOSURE AF and CHAMPION AF trials, highlighting that LAA closure provides stroke rates comparable to anticoagulation, with a key advantage in reducing bleeding risk. While a small signal of increased ischaemic stroke warrants further evaluation, the procedure is considered safe and particularly valuable for patients at high bleeding risk or unable to tolerate anticoagulation. Careful patient selection remains essential, with emerging interest in its use for patients experiencing stroke despite anticoagulation.
This interview was filmed at EuroPCR 2026: see more videos here.